crispr therapeutics ag biotechnology company headquartered zug switzerland one first companies formed utilize crispr gene editing platform develop medicines treatment various rare common company approximately employees offices zug switzerland boston massachusetts san francisco california london united kingdom manufacturing facility framingham massachusetts facilities year award foya award company lead program exagamglogene autotemcel exacel formerly submitted regulatory approval crispr therapeutics founded emmanuelle charpentier shaun foy rodger charpentier later shared nobel prize chemistry jennifer doudna part working group provided first scientific documentation development use crispr gene editing allows dna specifically modified edited used ameliorate diseases crispr therapeutics applying technology platform research develop commercialize medicines various diseases including sickle cell disease beta thalassemia various cancers type diabetes cardiovascular current ceo company samarth kulkarni phd joined company chief business officer kulkarni became ceo crispr therapeutics formed various collaborations support mission developing medicines vertex pharmaceuticals crispr therapeutics entered strategic research collaboration focused use discover develop potential new treatments aimed underlying genetic causes human one first potential treatments emerge joint research program exagamglogene autotemcel commonly known exacel subsequently crispr therapeutics vertex expanded collaboration include diseases like duchenne muscular dystrophy type company signed agreement bayer ag started operate casebia therapeutics joint venture bayer operated management crispr company went public nasdaq exchange october crispr therapeutics established partnerships number additional companies viacyte part vertex nkarta capsida curevac crispr therapeutics several drugs development blood diseases cancer diabetes severe diseases include drug exacel treatment rare blood disorders beta thalassemia sickle cell disease developed jointly vertex may exacel received orphan drug designation us food drug administration transfusiondependent beta thalassemia european medicines agency sickle cell disease transfusiondependent beta phase clinical trial results support safety efficacy rolling biologics license applications blas submitted us food drug administration fda exacel sickle cell disease transfusiondependent beta thalassemia additionally eu uk filings completed submissions validated european medicines agency medicines healthcare products regulatory httpsenwikipediaorgwikicrisprtherapeutics